Kent Crickard
State University of New York System
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kent Crickard.
Chemistry and Physics of Lipids | 2002
Herbert Schuel; Lani J. Burkman; Jack Lippes; Kent Crickard; Ellyn Forester; Daniele Piomelli; Andrea Giuffrida
N-Acylethanolamines (NAEs) are an important family of lipid-signaling molecules. Arachidonylethanolamide (anandamide) (AEA), palmitoylethanolamide (PEA), and oleoylethanolamide (OEA) are co-produced from similar phospholipid precursors when neurons are stimulated. AEA is an endogenous agonist (endocannabinoid) for cannabinoid receptors. It binds with higher affinity to type CB1 than to type CB2 cannabinoid receptors. PEA does not bind to CB1, while the hypothesis that it reacts with putative CB2-like receptors has been questioned. OEA does not activate currently known cannabinoid receptors, but it mimics the effects of AEA and cannabinoids in reducing the fertilizing capacity of sea urchin sperm. OEA and PEA also act as entourage compounds by inhibiting the hydrolysis of AEA by fatty acid amide hydrolase. Cannabinoid receptors and/or AEA are present in mammalian reproductive organs including the testis, epididymis, prostate, ovary, uterus, sperm, preimplantation embryo and placenta, as well as prostatic and mammary carcinomas. We now report that analysis by high-performance liquid chromatography/mass spectrometry (HPLC/MS) shows the presence of AEA, PEA, and OEA in human seminal plasma, mid-cycle oviductal fluid, follicular fluid, amniotic fluid, milk, and fluids from malignant ovarian cysts. Previous studies showed that AEA-signaling via cannabinoid receptors regulates capacitation and fertilizing potential of human sperm, early embryonic development and blastocyst implantation into the uterine mucosa of rodents, as well as proliferation of human mammary and prostatic carcinomas. Current results imply that NAEs also may modulate follicular maturation and ovulation, normal and pathological ovarian function, placental and fetal physiology, lactation, infant physiology, and behavior. Collectively, these findings suggest that NAEs in human reproductive fluids may help regulate multiple physiological and pathological processes in the reproductive system, and imply that exogenous cannabinoids delivered by marijuana smoke might impact these processes. This study has potential medical and public policy ramifications because of the incidence of marijuana abuse by adolescents and adults in our society, previously documented reproductive effects of marijuana, and the ongoing debate about medicinal use of marijuana and cannabinoids.
Clinical & Experimental Metastasis | 1987
Michael J. Niedbala; Kent Crickard; Ralph J. Bernacki
Better in vitro models arc needed to elucidate the mechanisms underlying tissue destruction by human tumor cells. To address this matter recently isolated and characterized human ovarian carcinoma cell lines derived from either primary tumors, ascitic effusions or metastatic growths were plated in direct contact with extracellular matrix (ECM) previously deposited on culture dishes by bovine corneal endothelial cells. Light and electron microscopy of four of the five ovarian tumor cell lines demonstrated morphologic digestion with penetration of ECM by tumor cell microvilli, along with associated rarefaction. The ability of these same ovarian tumor cell lines to solubilize specific carbohydrate and protein moieties present in intact ECM was assessed with the use of metabolically prelabeled ECM employing tritiated fucose, galactose, glucosamine and proline. Results from these studies corroborated morphologic observations in which four of the five tumor cell lines tested extensively solubilized radiolabeled ECM. The kinetics of radiolabel release from ECM illustrated that three of the four invasive tumors released [3H]fucose, [3H]glucosamine and [3H]proline at high rates. Normal human ovarian fibroblasts and mesothelial cells were observed to be unable to digest ECM and this was consistent with their inability to release radiolabeled material from prelabeled ECM. The results from these studies suggest that some ovarian carcinomas have the ability to degrade basement membrane components. Knowledge regarding the mechanisms responsible for tissue degradation may eventually lead to the development of new chemotherapeutic modalities designed to restrict tumor cell invasion, growth and metastasis.
Gynecologic Oncology | 1990
James Fanning; William C. Biddle; Martin Goldrosen; Kent Crickard; Ulla Crickard; M.Steven Piver; Kenneth A. Foon
Abstract In this study, we compared the cytotoxicity of cisplatin and carboplatin against a panel of human ovarian cancer cell lines using the MTT assay, a rapid colorimetric test that can be used to evaluate the number of residual viable tumor cells following chemotherapy. The established human ovarian cancer cell line OVCAR-3 and the recently isolated and characterized A721, A90, A286, A1, and A121A cell lines were evaluated for chemosensitivity. Each cell line was treated separately with cisplatin and carboplatin at concentrations ranging from 500 to 0.16 μg/ml. Various chemotherapeutic exposure periods (1, 4, 24, and 48 hr) were tested to determine maximal efficacy. All cell lines were more susceptible to cisplatin than carboplatin at all drug concentrations and all exposure periods tested ( P = 0.005). The overall median 50% inhibitory concentration (ID 50 ) for cisplatin was 107 μg/ml compared with 490 μg/ml for carboplatin ( P = 0.005). For both cisplatin and carboplatin a 24-hr exposure was significantly more cytotoxic than a 1-hr exposure ( P = 0.003 and P = 0.006, respectively). These in vitro results suggest that cisplatin is significantly more cytotoxic than carboplatin against human ovarian cancer cell lines and that cisplatin should not be replaced by carboplatin in the treatment of advanced epithelial ovarian cancer until randomized trials using maximum dosing of the cisplatin-containing regimen are performed.
Gynecologic Oncology | 1990
Chandrika Sreekantaiah; Kent Crickard; Ulla Crickard; Mahmood Yoonessi; Avery A. Sandberg
We report the cytogenetic findings in a primary endometrioid carcinoma of the ovary from a 29-year-old woman. Three clones with counts of 30, 29, and 27 chromosomes were observed. The predominant clone had 29 chromosomes and the following karyotype: 29, X, -X, -3, -3, +der(3)ins(3;?) (q21;?), -4, -5, -6, -8, -9, -11, -13, -14, -15, -16, -17, -18, -19, -21, -22, +mar. The clone with 30 chromosomes had an additional marker in the form of a minute chromosome, and the clone with 27 chromosomes was monosomic for chromosomes 12 and 20 also. Interestingly, there was no nullisomy of any of the chromosomes.
Journal of Assisted Reproduction and Genetics | 2005
Mohamed F.M Mitwally; Hemlata S. Bhakoo; Kent Crickard; Michael W. Sullivan; Ronald E. Batt; John Yeh
Purpose Most studies reported estradiol (E2) levels attained on day of hCG administration when investigating effect of E2 on IVF outcome. We studied whether a relationship exists between the area under the curve for E2 levels (AUC-E2) and E2 levels on hCG day during IVF-ET.Methods Retrospectively, we analyzed data for 313 patients who completed one IVF-ET cycle each. Patients were sorted according to AUC-E2 levels. Then we compared between each patient’s own AUC-E2 and the corresponding E2 level on hCG day for the same patient.Results Although overall AUC-E2 correlated positively with E2 levels on hCG day, there was no consistent correlation between individual patients.Conclusions AUC-E2 reflects more accurately the amount of E2 produced by the follicles during controlled ovarian hyperstimulation. The absence of a uniform correlation between AUC-E2 and E2 on hCG day may result in different conclusions when studying outcomes of IVF treatment.
Gynecologic Oncology | 1994
Kent Crickard; Janet L. Gross; Ulla Crickard; Mahmood Yoonessi; Shashikant Lele; William F. Herblin; Kristi Eidsvoog
Fertility and Sterility | 2006
Mohamed F. M. Mitwally; Helmata S. Bhakoo; Kent Crickard; Michael W. Sullivan; Ronald E. Batt; John Yeh
Cancer Research | 1983
Kent Crickard; Ulla Crickard; Mahmood Yoonessi
Cancer Research | 1987
Michael J. Niedbala; Ragupathy Madiyalakan; Khushi L. Matta; Kent Crickard; Moheswar Sharma; Ralph J. Bernacki
Fertility and Sterility | 2003
Mohamed F.M Mitwally; Hemlata S. Bhakoo; Kent Crickard; Michael W. Sullivan; Ronald E. Batt; John Yeh
Collaboration
Dive into the Kent Crickard's collaboration.
University of Texas Health Science Center at San Antonio
View shared research outputs